India, May 20 -- Royal Philips (PHG) Tuesday announced that it has initiated the RADIQAL (Radiation Dose and Image Quality Trial), a multicenter, randomized clinical study focused on evaluating a new ultra-low X-ray dose technology for coronary procedures.
The trial will include 824 patients with coronary artery disease (CAD) across six hospitals located in Spain, the Czech Republic, and the United States. The first participant was enrolled at Aarhus University Hospital in Denmark.
The RADIQAL trial aims to assess radiation exposure, image quality, and procedural performance by comparing Philips' latest ultra-low dose protocol with the existing ClarityIQ technology, both integrated into the company's Azurion image-guided therapy system. T...